Roche To Slash Prices Of Two Cancer Medications In India
Mon, 03/26/2012 - 07:48 | 
The Swiss pharmaceutical firm Roche Holding AG has decided to offer sharply discounted editions of two cancer medications in the Indian market.
Patients will expire because of the administration's reforms to the NHS, the editor of a respected medical journal claimed yesterday.
Teva Pharmaceutical Industries, the globe's largest generic drug manufacturer, plans to offer senior notes denominated in euros and Swiss francs outside the US.
Watson Pharmaceuticals soared during noon trading on Wednesday after an anonymously sourced report stated that it is near to buying Swiss counterpart Actavis.
Tags: Natco Pharma Bags Obligatory Licence; Pharma Sector Calls Budget A Complete Disappointment
The verdict to permit Natco Pharma to market Bayer's patented cancer medication Nexavar has divided the pharmaceutical business with domestic companies welcoming it whereas MNCs stated 'arbitrarily' utilization of compulsory licenses will destabilize novelty in the division.
As usual, the pharmaceutical sector has called the Union Budget a complete disappointment. Though Pranab Mukherjee has given a big bonanza to the pharma division via extension of the 200% weighted subtraction for R&D spending, raise in service tax to 12% has come as a blow to the division.
Shasun Pharmaceuticals has completed the sale of Velachery possessions for around Rs 29 crore and also announced interim dividend of Rs 2 a share, the reports said.
Lupin Bags USFDA Authorization For Fenofibrate; Zydus Cadila To Back Away From Drug Discovery Pact With Eli Lilly
Lupin Pharmaceuticals Ltd has bagged final authorization for its Fenofibrate Tabs, 48 mg and 145 mg potencies from
the USFDA.
Teva Pharmaceutical Industries Ltd stated that President and Chief Executive Shlomo Yanai would quit during May, after over 5 years at the helm.
Research based Indian pharma firms are ready to detain a key share of the US domestic market with growing number of filing of ANDAs.
Indian pharmaceutical firm, Zydus Cadila is eyeing to back out from its alliance with Eli Lilly, which involved combined drug detection for cardiovascular illnesses.
